Combination of general and local action drugs in treatment of patients with generalized periodontitis on the basis of the pathology of the hepatobiliary system

Anastasiya Furdychko1, Anna Buchkovska1, Olga Petryshyn1, Volodymyr Hrynovets1, Taras Chaban2, Ihor Hrynovets3, Stefan Harkov4, Ihor Chaban5

1 Department of Therapeutic Dentistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine
2 Department of General, Bioorganic, Physical and Colloidal Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine
3 Department of Technology of Medications and Biopharmaceutics, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine
4 Department of Pharmacy, Medical College of Burgas University “Prof. Dr. Asen Zlatarov”, St. Stambolov 69 Bv., Burgas, 8000, Bulgaria
5 Department of Pharmaceutical Chemistry FPGE, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine

Corresponding author: Taras Chaban (chabantaras@ukr.net)

Received 4 April 2019 ♦ Accepted 3 June 2019 ♦ Published 13 May 2020

Citation: Furdychko A, Buchkovska A, Petryshyn O, Hrynovets V, Chaban T, Hrynovets I, Harkov S, Chaban I (2020) Combination of general and local action drugs in treatment of patients with generalized periodontitis on the basis of the pathology of the hepatobiliary system. Pharmacia 67(1): 13–16. https://doi.org/10.3897/pharmacia.67.e35147

Abstract

The pathology of the hepatobiliary system significantly affects the state of the organs of the oral cavity. A clinical and index study of the state of periodontal tissues in 122 patients was conducted, which showed the prevalence of periodontal disease in patients with chronic acalculous cholecystitis. The examined patients were divided into groups depending on the treatment method, and the result was evaluated before treatment, directly after treatment and 6 months following treatment. Antidysbiotic hepatoprotector and 2% thiotriazolin ointment were included in the combination therapy. Studies have shown that patients with hepatobiliary pathology have increased likelihood of periodontal diseases, and after treatment, periodontal indicators and the hygiene index are significantly reduced, especially in the group where the proposed scheme was used, and the long-term results were stable for 6 months.

Copyright Furdychko A et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
**Keywords**
hepatobiliary pathology, hepatoprotector, prebiotic, periodontitis, thiotriazolin

**Introduction**

An important place in scientific research is held by the study of the development of periodontal diseases and their relationship to diseases of the hepatobiliary system (Shay 2002). Disturbances of the barrier function of the liver plays a decisive role in the pathogenesis of hepatoboar syndrome, because opportunistic and pathogenic microorganisms invade the circulatory system with subsequent damage to various organs and systems of the body, including tissues of the oral cavity (Xiaojing et al. 2000; Levitskiy and Demyanenko 2008). Patients with hepatobiliary pathology could have such dental diseases as catarrhal and atrophic gingivitis, periodontitis, xerostomia, glossitis, hyperplasia of enamel and dentin (Levitskiy 2012).

It has been proven that the functional activity of the hepatobiliary system is negatively affected by intestinal dysbacteriosis (Furdychko et al. 2018), which affects most of the population of Ukraine. Therefore, the use of anti-dysbiotic agents that eliminate dysbiosis and have hepatoprotective effect are appropriate.

The aim of the present study was to include in the integrated therapy anti-dysbiotic hepatoprotector “Lekvin” (Levitskiy et al. 2016), and 2% thiotriazolin ointment (Sulyam 2010, Sulyam et al. 2014; Buchkovska et al. 2011; Mashchenko 2003) as well as to analyze the data of clinical and instrumental studies of the state of periodontal tissues, which included the hygiene index, the index assessment of periodontal tissue pathology and the index of bleeding gums, patients with chronic acalculous cholecystitis.

Groups are peer in number; the age of the patients was 25–46 years, of which 64.9% (48/74) were females, and 35.1% (26/74) – males.

Criteria for inclusion were patients with chronic initial-stage I GP with concomitant chronic diseases of the hepatobiliary system, in particular CAC, who had no contraindications to treatment with the proposed methods and drugs that clearly followed the recommendations of the physician and provided informed consent for the study and treatment. Criteria for exclusion were patients with: dentoalveolar deformations and anomalies of dentition, pathological abrasion, orthodontic devices, patients with chronic viral hepatitis, HIV-infection, active tuberculosis, the presence of concomitant diseases of other organs and systems, tumors of any localization, the patient’s refusal of examination and treatment.

Patient examination included history taking, objective examination of the oral cavity: the Green-Vermillion hygiene index (GVI), PMA index (Parma 1960), and papilla bleeding index (PBI) [8] were determined. The state of the hepatobiliary system in patients was assessed by the doctors of the gastroenterology department of the Zolochiv district hospital in the Lviv region. Patients with hepatobiliary pathology received treatment by specialists in this area in accordance with the protocol of treatment. The examination was performed prior to treatment, immediately after treatment and 6 months following treatment.

The mathematical processing of the results of the study was carried out using the "EXCEL" and "STATISTICA" software.

**Experimental part**

**Materials and methods**

A total of 122 patients were screened – 20 apparently healthy persons without periodontal pathologies (12 female and 8 male) that constituted the control group and 102 patients with initial to stage I generalized periodontitis (initial-stage I GP). Patients with periodontal pathology were divided into several groups: 28 patients without somatic diseases (comparison group) and 74 patients with chronic acalculous cholecystitis (CAC). Of these, 38 patients (Group I) received treatment provided by the Protocol on medical care in the field of therapeutic dentistry, and 36 patients, in addition to basic therapy, took "Lekvin" as an anti-dysbiotic agent and 2% thiotriazolin ointment (group II). 1–2 tablets 2–3 times daily after a meal of anti-dysbiotic "Lekvin" were prescribed in this group. After antiseptic treatment, 2% thiotriazolin ointment was applied to the gums.

A total of 122 patients were screened – 20 apparently healthy persons without periodontal pathologies (12 female and 8 male) that constituted the control group and 102 patients with initial to stage I generalized periodontitis (initial-stage I GP). Patients with periodontal pathology were divided into several groups: 28 patients without somatic diseases (comparison group) and 74 patients with chronic acalculous cholecystitis (CAC). Of these, 38 patients (Group I) received treatment provided by the Protocol on medical care in the field of therapeutic dentistry, and 36 patients, in addition to basic therapy, took "Lekvin" as an anti-dysbiotic agent and 2% thiotriazolin ointment (group II). 1–2 tablets 2–3 times daily after a meal of anti-dysbiotic "Lekvin" were prescribed in this group. After antiseptic treatment, 2% thiotriazolin ointment was applied to the gums.

**Results and discussion**

Table 1 presents the results of an index assessment of the state of periodontal tissues in the patients before treatment. The PMA index was determined to be the highest in the group of patients with initial-stage I GP and CAC (59.39 ± 0.29). It significantly (p < 0.001) exceeded the same index both in the group of patients without pathology of the biliary tract (55.85 ± 0.61) and in the control group. The Green-Vermillion index was the highest in the group of patients with initial-stage I GP and CAC (1.73 ± 0.01); it significantly (p < 0.001) exceeded the indicator in the group of patients with initial-stage I GP and CAC (0.44 ± 0.07) and in the one with initial-stage I GP (1.63 ± 0.03). We see the same data by analyzing the indicators of the papilla bleeding index – the highest value was 1.68 ± 0.03 in the group of patients with initial-stage I GP and CAC, and the lowest (1.44 ± 0.43) – in patients without somatic pathology.
Thus, the periodontal status of patients with hepatobiliary pathology is much worse.

Table 2 presents the results of an index assessment of the state of periodontal tissues in the patients before treatment, after treatment and 6 months following treatment.

The state of gums of all patients with GP after the completion of combination treatment normalized, discomfort in the oral cavity disappeared, which was manifested by the absence of complaints and edema, gums attach more tightly to the neck of the teeth and their consistency and contour improved. Achieved results remained six months later.

**Conclusions**

Analyzing the data of clinical and instrumental studies of the state of periodontal tissues, which included the hygiene index, the index assessment of periodontal tissue pathology and the papilla bleeding index, of patients with chronic acalculous cholecystitis, it was found that the clinical course of initial-stage I generalized periodontitis depends on the lesion of hepatobiliary tract. Thus, the severity of the inflammatory periodontal diseases depends on the activity of the pathology of the hepatobiliary system.

Moreover, analyzing the indicators after treatment, we can see that inclusion of the antidepressant “Lekvin” and 2% thiotriazolin ointment in the combination treatment significantly improves the Green-Vermillion index, PMA index (papillary-marginal-alveolar index (P), the gingival margin (M), and the attached gingiva (A), and reduces papilla bleeding index (PBI). Therefore, the proposed remedies are advisable to use in combination therapy to improve the efficacy of treatment.

**References**

Buchkovska AYu, Mazur IA, Stets VR, Voloshyn MA (2011) Patent 43218 Ukraine, IPC (2011) A61K 31/00. Wound healing agent thiotriazolin ointment. Published 15.11.2011. – Bull No. 10.

Furdychko AI, Hasiuk PA., Ivanchyshyn VV , Hasiuk NV (2018) Clinical-laboratory justification of dependence of periodontal inflammatory diseases on the condition of hepatobiliary system. Svit medycyny 1(63): 87–89. https://doi.org/10.26724/2079-8334-2018-1-63-87-89

Levitskiy AP, Demyanenko SA (2008) The role of the liver in the pathogenesis and treatment of dental diseases. Herald of Dentistry 5–6: 124–128.

Levitskiy AP (2012) Hepatooral syndrome. 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group, February 2012.140.

Levitskiy AP, Makarenko OA, Selivanovska IO, Furdychko AI, Stupak OP, Denga OV (2016) Patent 108536 Ukraine, IPC (2015) A61K 36/00. Antidysbiotic Lekvin. Published 25.07.2016. – Bull No. 14.

Maschenko IS (2003) Periodontal Diseases. Dnepro, Kolo; 2003, 272 pp.

Levitskiy AP (2012) Hepatooral syndrome. 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group, February 2012.140.

Levitskiy AP, Malarenko OA, Selivanovska IO, Furdychko AI, Stupak OP, Denga OV (2016) Patent 108536 Ukraine, IPC (2015) A61K 36/00. Antidysbiotic Lekvin. Published 25.07.2016. – Bull No. 14.

Shay K (2002) Infectious complications of dental and periodontal diseases in the elderly population. Clinical Infectious Diseases 34(9): 1215–1223. https://doi.org/10.1086/339865

**Table 1.** Index characteristics of the state of periodontal tissues in patients with initial-stage I GP with and without pathology of the hepatobiliary system (M ± m).

| Healthy (control group), n=20 | Patients with the initial-stage I GP, without somatic pathology (comparison group) n=28 | Patients with the initial-stage I GP and CAC (groups I and II) n=74 |
|-----------------------------|---------------------------------------------------|---------------------------------------------------------------|
| FMA, % | 0 | 55.85 ± 0.61* | 59.39 ± 0.29 |
| GVI, units | 0.44 ± 0.07 | 1.63 ± 0.03* | 1.73 ± 0.01* |
| PBI, points | 0 | 1.44 ± 0.43* | 1.68 ± 0.03* |

Note:

* – the probability indicator (p<0.05) in comparison with the control group;
# – probability indicator (p<0.05) in comparison with the comparison group.

**Table 2.** Changes of clinical indices over time in patients with initial-stage I GP under the influence of combination treatment (M ± m).

| Groups | PMA, % | GVI, units | PBI, points |
|--------|--------|------------|------------|
| Control group (n=20) | 0 | 0.44 ± 0.07 | 0 |
| I group (n=38) | Before the treatment | 59.40 ± 0.41* | 1.73 ± 0.12* | 1.72 ± 0.04* |
| After the treatment | 6.68 ± 0.36**× | 0.41 ± 0.03**× | 0.17 ± 0.010**× |
| 6 months after the treatment | 7.74 ± 0.35*** | 0.43 ± 0.02*** | 0.21 ± 0.003**° |
| II group (n=36) | Before the treatment | 59.37 ± 0.41* | 1.72 ± 0.12* | 1.63 ± 0.00* |
| After the treatment | 5.17 ± 0.09**× | 0.22 ± 0.06**× | 0.12 ± 0.01**× |
| 6 months after the treatment | 5.26 ± 0.17*** | 0.36 ± 0.02*** | 0.18 ± 0.003**° |

Note: there is no significant difference between the groups of patients with the initial-stage I GP and CAC before the treatment.

* – probability indicator (p<0.05) in comparison with the control group;
# – probability indicator (p<0.05) in comparison with the group before the treatment;
° – probability indicator (p<0.05) in comparison with the group after the treatment.

× – probability indicator (p<0.05) compared to the group 6 months following the treatment.
Sulym YuV (2010) Application of polymer films with decamethoxin and thiatriazolin for the treatment of inflammatory diseases of the mucous membrane of the mouth. Ukrainian Dental Almanac 2: 117–118.

Sulym Yu, Buchkovska A, Petryshyn O (2014) Usage of gels and films for treatment of inflammatory diseases of mucous membrane of oral cavity and periodontitis. Experimental and Clinical Physiology and Biochemistry 4: 72–79. http://ecpb.org.ua/archive/68/4/72

Xiaojing L, Kolltveit KM, Tronstad L, Olsen I (2000) Systemic diseases caused by oral infection. Clinical Microbiology Reviews 13(4): 547–558. https://doi.org/10.1128/CMR.13.4.547